Aragonite compositions, methods, and uses thereof
Compositions, methods, and uses of calcium carbonate-based composition are presented. The calcium carbonate-based composition includes a plurality of restructured calcium carbonate particles that has an average size of equal or less than 10 microns in diameter. Preferably, the calcium carbonate-based composition is generated by unstructuring the aragonite using an acid and a chelator and recrystallizing the unstructured aragonite in a customized form. Exemplary aragonite-based compositions include pavement compositions.
1 . A calcium carbonate-based composition, comprising:
a plurality of restructured oolitic aragonite particles coated with a positively charged coating, and a carrier;
wherein the restructured oolitic aragonite particles comprises oolitic aragonite particles that are treated with an acid and a chelator to unstructure the aragonite particles, and the unstructured aragonite particles are recrystallized to form restructured politic aragonite particles;
wherein the restructured oolitic aragonite particles have an average diameter of less than or equal to 10 μm;
wherein a negatively charged bioactive agent is bound to the positively charged coating;
wherein the restructured oolitic aragonite particles are modified to deliver the negatively charged bioactive agent to a target cell or target tissue in a mammal when the composition is administered to the mammal; and
wherein the bioactive agent is negatively charged at physiological pH.
2 . The composition of claim 1 , wherein the particles are in a sterile pharmaceutically acceptable solution for injection and/or infusion.
3 . The composition of claim 1 , wherein the modified aragonite particles have an average particle diameter of between 100 nm and 10 μm.
4 . The composition of claim 1 , wherein the modified aragonite particles have an average particle diameter of between 10 nm and 1 μm.
5 . The composition of claim 1 , wherein the carrier comprises a detergent, and optionally at least one of a viscosity agent, a flavorant, an antibacterial agent, and a whitening agent.
6 . The composition of claim 5 , wherein the carrier is formulated as a toothpaste.
7 . The composition of claim 5 , wherein the negatively charged bioactive agent is a fluoride anion.
8 . The composition of claim 7 , wherein the fluoride anion is present in a salt form, and wherein the salt form is coated onto or interspersed with the modified aragonite particles.
9 . The composition of claim 7 , wherein the positively charged coating is a cationic compound that is bound to the modified aragonite particles, and wherein the fluoride anion is bound to the positively charged coating.
10 . The composition of claim 9 , wherein the cationic compound is a cationic lipid a lipopolyamine, 1,2-dioleoyloxy-3-(trimethylammonio) propane (DOTAP), dimethyldioctadecyl-ammonium (DDA), 1,2-dimyristoyl-3-trimethylammonium propane (DMTAP), and/or dipalmitoyl-trimethylammonium propane (DPTAP).
11 . The composition of claim 9 , wherein the cationic compound is distearoyl-trimethylammonium propane (DSTAP).
12 . The composition of claim 1 , wherein the carrier is formulated for injection.
13 . The composition of claim 12 , wherein the negatively charged bioactive agent is a nucleic acid.
14 . The composition of claim 13 , wherein the nucleic acid is an RNA that encodes an antigen of a pathogen or that encodes an antigen of a neoplastic cell or cancer cell.
15 . The composition of claim 13 , wherein the nucleic acid is bound to a cationic compound that is bound to the modified aragonite particles.
16 . A method of preparing a calcium carbonate-based composition, comprising:
providing oolitic aragonite particles, and treating the aragonite with an acid and a chelator to unstructure the aragonite particles;
recrystallizing the unstructured aragonite particles to form restructured oolitic aragonite particles; and
coupling to or including in the restructured oolitic aragonite particles a negatively charged bioactive agent that is negatively charged at physiological pH.
17 . The method of claim 16 , wherein the restructured oolitic aragonite particles have an average particle diameter of between 100 nm and 10 μm.
18 . The method of claim 16 , wherein the bioactive agent is coupled to the restructured oolitic aragonite particles via a cationic compound that is bound to the restructured politic aragonite particles.
19 . The method of claim 16 , wherein the negatively charged bioactive agent is a fluoride anion and wherein the composition is formulated as a toothpaste.
20 . The method of claim 16 , wherein the negatively charged bioactive agent is a nucleic acid and wherein the composition is formulated as a vaccine composition.